Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Northwest Biotherapeutics Q3 2026 Results: Net Loss of $28.8M, Loss Widens

Northwest Biotherapeutics reported a net loss of $41.1 million for the nine months ended September 30, 2026, an improvement from the $61.6 million loss in the prior year period. Total revenues increased to $2.2 million from $0.7 million, while operating expenses decreased significantly from $47.1 million to $34.6 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.90.2
Net income-28.8-26.8
EPS (diluted, $ a share)$-0.02$-0.02

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+341.5%
Source

10-Q filed with the SEC, OTC: NWBO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Northwest Biotherapeutics Inc: key numbers

Share price
$0.1462Close, Nov 16
Market cap
$265M
Shares outstanding
1.81BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Northwest Biotherapeutics Inc

All →
4:10 PM ET 8-K
Loan & Debt

Northwest Biotherapeutics $5.5M Debt Financing with Streeterville Capital, LLC

Northwest Biotherapeutics entered into a $5.505 million commercial loan agreement and note with Streeterville Capital, LLC. The loan carries an 8% annual interest rate, a 10% original issue discount, and a 22-month maturity with no repayments required for the first 8 months. Proceeds will be used to fund the company's ongoing business operations.

Value
$5.5M
Counterparty
Streeterville Capital, LLC
Term
22 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.